Schering-Plough Submits Response to FDA for SAPHRIS(TM) (asenapine) in the Acute Treatment of Both Schizophrenia and Bipolar I Disorder
Posted on: Friday, 20 February 2009, 06:30 CST
Response submitted within one month of FDA complete response letter
The action letter included proposed labeling for both indications and a request for supplemental data from the existing asenapine database. No additional clinical trials were requested.
"We are pleased to have submitted the SAPHRIS complete response within a month from receipt of the FDA action letter. We look forward to working with the agency to finalize labeling and gain approval, and to bringing a new therapy to patients with schizophrenia and bipolar I disorder," said
Schering-Plough acquired asenapine in
Schering-Plough is an innovation-driven, science-centered global health care company. Through its own biopharmaceutical research and collaborations with partners, Schering-Plough creates therapies that help save and improve lives around the world. The company applies its research-and-development platform to human prescription, animal health and consumer health care products. Schering-Plough's vision is to "Earn Trust, Every Day" with the doctors, patients, customers and other stakeholders served by its colleagues around the world. The company is based in
SCHERING-PLOUGH DISCLOSURE NOTICE: The information in this press release includes certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the clinical development of, the commercial plans for and the potential market for SAPHRIS. Forward-looking statements relate to expectations or forecasts of future events. Schering-Plough does not assume the obligation to update any forward-looking statement. Many factors could cause actual results to differ materially from Schering-Plough's forward-looking statements, including uncertainties in the regulatory process, among other uncertainties. For further details about these and other factors that may impact the forward-looking statements, see Schering-Plough's Securities and Exchange Commission filings, including Part II, Item 1A. "Risk Factors" in the third quarter 2008 10-Q, filed
SOURCE Schering-Plough Corporation
Source: PR Newswire
Related Articles
- Schering-Plough Reports Data From SAPHRIS(R) (asenapine) Long-Term Schizophrenia Relapse Prevention Study
- Video: Schering-Plough Announces FDA Approval of SAPHRIS(R) (asenapine) for Acute Treatment of Schizophrenia In Adults and Manic or Mixed Episodes of Bipolar I Disorder With or Without Psychotic Features In Adults
- Schering-Plough Announces European Filing of SYCREST(R) (asenapine) for the Treatment of Schizophrenia and Bipolar I Disorder
- Schering-Plough Highlights Hepatitis C Clinical Data Presentations at the European Association for the Study of the Liver (EASL) Annual Meeting
- U.S. FDA Issues Complete Response Letter for SAPHRIS(TM) (ASENAPINE) in the Acute Treatment of Both Schizophrenia and Bipolar I Disorder
- Schering-Plough Announces Asenapine NDA Accepted for Filing By the U.S. FDA
- Schering-Plough Reports Two Phase II Studies of Thrombin Receptor Antagonist (TRA) Build on Findings From Previous Phase II Study
- Schering-Plough Announces Initiation of Two Phase III Clinical Trials for Novel Selective Antiplatelet Therapy (TRA-SCH 530348)
- Despite Superior Efficacy on Psoriatic Plaque Clearance, Centocor/Schering- Plough/Tanabe's Remicade Will Be Supplanted As the Clinical Gold Standard for the Treatment of Moderate-to-Severe Psoriasis By 2015
 |
 |
User Comments (0)
RSS Feeds